Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):883–891. doi: 10.1038/sj.bjc.6690436

Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR

T J de Vries 1,1, A Fourkour 1, C J A Punt 2, L T F van de Locht 3, T Wobbes 4, S van den Bosch 5, M J M de Rooij 6, E J B M Mensink 3, D J Ruiter 1, G N P van Muijen 1
PMCID: PMC2362284  PMID: 10360670

Abstract

In recent years, large discrepancies were described in the success rate of the tyrosinase reverse transcription polymerase chain reaction (RT-PCR) for detecting melanoma cells in the peripheral blood of melanoma patients. We present a quality control study in which we analysed the reproducibility of detection of tyrosinase and MART-1 transcripts in 106 blood samples from 68 melanoma patients (mainly stages III and IV). With this study, we aimed to improve insight in the reproducibility of a RT-PCR for the detection of (minimal) amounts of circulating melanoma cells. We performed two reverse transcriptions on each mRNA sample and performed tyrosinase and MART-1 nested PCRs in duplicate per cDNA sample. Thus, four tyrosinase and four MART-1 measurements were performed per blood sample. In our study, the majority of blood samples was negative for tyrosinase (80%) or MART-1 (66%). Only four samples were positive in all four determinations for tyrosinase and seven for MART-1. Variable results (1–3 times positive results) were obtained for tyrosinase and MART-1 in 16% and 27% respectively. MART-1 PCR had a better performance than tyrosinase PCR. Sensitivity increased when both markers were used. We reasoned that the low number of melanoma marker PCR-positive blood samples can be explained by differences in mRNA quality. By using real-time quantitative PCR, we found that this was not the case: amplification of porphobilinogen deaminase (PBGD), a low copy household gene, was not different in blood samples in which a melanoma marker was not detected from groups in which this marker was detected more or less consistently (1–4 times). When applying real-time quantitative PCR for tyrosinase and MART-1, we found that a low amount of SK-MEL-28 cell equivalents was present in the blood of melanoma patients, with a higher number of equivalents in the group with a consistently positive result. We conclude that low reproducibility of a repeated assay for the detection of circulating melanoma cells is not caused by differences in mRNA quality between the samples, but due to low numbers of amplifiable target mRNA molecules in the mRNA sample. Use of more than one marker and repetition of the assay will increase the probability of finding positive PCR results. © 1999 Cancer Research Campaign

Keywords: tyrosinase, MelanA/MART-1, circulating cancer cells, melanoma, quantitative RT-PCR

Full Text

The Full Text of this article is available as a PDF (164.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battayani Z., Grob J. J., Xerri L., Noe C., Zarour H., Houvaeneghel G., Delpero J. R., Birmbaum D., Hassoun J., Bonerandi J. J. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol. 1995 Apr;131(4):443–447. [PubMed] [Google Scholar]
  2. Brandt B., Junker R., Griwatz C., Heidl S., Brinkmann O., Semjonow A., Assmann G., Zänker K. S. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 1996 Oct 15;56(20):4556–4561. [PubMed] [Google Scholar]
  3. Brossart P., Keilholz U., Scheibenbogen C., Möhler T., Willhauck M., Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):38–41. doi: 10.1097/00002371-199401000-00005. [DOI] [PubMed] [Google Scholar]
  4. Brossart P., Keilholz U., Willhauck M., Scheibenbogen C., Möhler T., Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol. 1993 Dec;101(6):887–889. doi: 10.1111/1523-1747.ep12371713. [DOI] [PubMed] [Google Scholar]
  5. Brossart P., Schmier J. W., Krüger S., Willhauck M., Scheibenbogen C., Möhler T., Keilholz U. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 1995 Sep 15;55(18):4065–4068. [PubMed] [Google Scholar]
  6. Burchill S. A., Bradbury F. M., Smith B., Lewis I. J., Selby P. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer. 1994 Jun 1;57(5):671–675. doi: 10.1002/ijc.2910570510. [DOI] [PubMed] [Google Scholar]
  7. Buzaid A. C., Balch C. M. Polymerase chain reaction for detection of melanoma in peripheral blood: too early to assess clinical value. J Natl Cancer Inst. 1996 May 1;88(9):569–570. doi: 10.1093/jnci/88.9.569. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Farthmann B., Eberle J., Krasagakis K., Gstöttner M., Wang N., Bisson S., Orfanos C. E. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol. 1998 Mar;110(3):263–267. doi: 10.1046/j.1523-1747.1998.00131.x. [DOI] [PubMed] [Google Scholar]
  10. Foss A. J., Guille M. J., Occleston N. L., Hykin P. G., Hungerford J. L., Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer. 1995 Jul;72(1):155–159. doi: 10.1038/bjc.1995.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ghossein R. A., Coit D., Brennan M., Zhang Z. F., Wang Y., Bhattacharya S., Houghton A., Rosai J. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res. 1998 Feb;4(2):419–428. [PubMed] [Google Scholar]
  12. Gibson U. E., Heid C. A., Williams P. M. A novel method for real time quantitative RT-PCR. Genome Res. 1996 Oct;6(10):995–1001. doi: 10.1101/gr.6.10.995. [DOI] [PubMed] [Google Scholar]
  13. Gläser R., Rass K., Seiter S., Hauschild A., Christophers E., Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol. 1997 Aug;15(8):2818–2825. doi: 10.1200/JCO.1997.15.8.2818. [DOI] [PubMed] [Google Scholar]
  14. Heid C. A., Stevens J., Livak K. J., Williams P. M. Real time quantitative PCR. Genome Res. 1996 Oct;6(10):986–994. doi: 10.1101/gr.6.10.986. [DOI] [PubMed] [Google Scholar]
  15. Higuchi R., Fockler C., Dollinger G., Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) 1993 Sep;11(9):1026–1030. doi: 10.1038/nbt0993-1026. [DOI] [PubMed] [Google Scholar]
  16. Holland P. M., Abramson R. D., Watson R., Gelfand D. H. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7276–7280. doi: 10.1073/pnas.88.16.7276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoon D. S., Yuzuki D., Hayashida M., Morton D. L. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol. 1995 Jan 15;154(2):730–737. [PubMed] [Google Scholar]
  18. Johnson P. W., Burchill S. A., Selby P. J. The molecular detection of circulating tumour cells. Br J Cancer. 1995 Aug;72(2):268–276. doi: 10.1038/bjc.1995.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jung F. A., Buzaid A. C., Ross M. I., Woods K. V., Lee J. J., Albitar M., Grimm E. A. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug;15(8):2826–2831. doi: 10.1200/JCO.1997.15.8.2826. [DOI] [PubMed] [Google Scholar]
  20. Jung R., Ahmad-Nejad P., Wimmer M., Gerhard M., Wagener C., Neumaier M. Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Eur J Clin Chem Clin Biochem. 1997 Jan;35(1):3–10. [PubMed] [Google Scholar]
  21. Keilholz U., Willhauck M., Rimoldi D., Brasseur F., Dummer W., Rass K., de Vries T., Blaheta J., Voit C., Lethé B. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer. 1998 Apr;34(5):750–753. doi: 10.1016/s0959-8049(97)10105-8. [DOI] [PubMed] [Google Scholar]
  22. Keilholz U., Willhauck M., Scheibenbogen C., de Vries T. J., Burchill S. Polymerase chain reaction detection of circulating tumour cells. EORTC Melanoma Cooperative Group, Immunotherapy Subgroup. Melanoma Res. 1997 Aug;7 (Suppl 2):S133–S141. [PubMed] [Google Scholar]
  23. Kunter U., Buer J., Probst M., Duensing S., Dallmann I., Grosse J., Kirchner H., Schluepen E. M., Volkenandt M., Ganser A. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 1996 May 1;88(9):590–594. doi: 10.1093/jnci/88.9.590. [DOI] [PubMed] [Google Scholar]
  24. Livak K. J., Flood S. J., Marmaro J., Giusti W., Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 1995 Jun;4(6):357–362. doi: 10.1101/gr.4.6.357. [DOI] [PubMed] [Google Scholar]
  25. Mellado B., Colomer D., Castel T., Muñoz M., Carballo E., Galán M., Mascaró J. M., Vives-Corrons J. L., Grau J. J., Estapé J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 1996 Jul;14(7):2091–2097. doi: 10.1200/JCO.1996.14.7.2091. [DOI] [PubMed] [Google Scholar]
  26. Mori M., Mimori K., Inoue H., Barnard G. F., Tsuji K., Nanbara S., Ueo H., Akiyoshi T. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 1995 Aug 1;55(15):3417–3420. [PubMed] [Google Scholar]
  27. Pittman K., Burchill S., Smith B., Southgate J., Joffe J., Gore M., Selby P. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol. 1996 Mar;7(3):297–301. doi: 10.1093/oxfordjournals.annonc.a010575. [DOI] [PubMed] [Google Scholar]
  28. Reinhold U., Lüdtke-Handjery H. C., Schnautz S., Kreysel H. W., Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol. 1997 Feb;108(2):166–169. doi: 10.1111/1523-1747.ep12333341. [DOI] [PubMed] [Google Scholar]
  29. Schoenfeld A., Luqmani Y., Smith D., O'Reilly S., Shousha S., Sinnett H. D., Coombes R. C. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 1994 Jun 1;54(11):2986–2990. [PubMed] [Google Scholar]
  30. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991 Nov 16;338(8777):1227–1229. doi: 10.1016/0140-6736(91)92100-g. [DOI] [PubMed] [Google Scholar]
  31. Stevens G. L., Scheer W. D., Levine E. A. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):293–296. [PubMed] [Google Scholar]
  32. Van der Velde-Zimmermann D., Roijers J. F., Bouwens-Rombouts A., De Weger R. A., De Graaf P. W., Tilanus M. G., Van den Tweel J. G. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol. 1996 Sep;149(3):759–764. [PMC free article] [PubMed] [Google Scholar]
  33. de Vries T. J., Fourkour A., Wobbes T., Verkroost G., Ruiter D. J., van Muijen G. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997 Aug 1;57(15):3223–3229. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES